-
1.发明授权Anti-idiotypic antibodies which induce an immune response against epidermal growth factor receptor 失效诱导针对表皮生长因子受体的免疫应答的抗独特型抗体
公开(公告)号：US5969107A
公开(公告)日：1999-10-19
申请号：US653402
申请日：1996-05-24
申请人： Ana Carceller , Elisabet Rosell , Alicia Gomez , Jaume Adan , Jaume Piulats
发明人： Ana Carceller , Elisabet Rosell , Alicia Gomez , Jaume Adan , Jaume Piulats
IPC分类号： C12N15/09 , A61K38/00 , A61K39/395 , A61P35/00 , C07K14/705 , C07K16/00 , C07K16/42 , C12N15/02 , C12P21/08 , C12R1/91
CPC分类号： C07K16/4258 , A61K38/00
摘要： The present invention relates to anti-idiotypic antibodies which induce an immune response against tumors, bearing as antigen the epidermal growth factor receptor (EGFR). The antibodies of the invention may mimic said antigen. As preferred embodiment the antibodies of the invention derive from mAB 425 (ATCC HB 9629) or a humanized or chimeric derivative thereof.
摘要翻译： 本发明涉及诱导针对肿瘤的免疫应答的抗独特型抗体，其作为抗原为表皮生长因子受体（EGFR）。 本发明的抗体可以模拟所述抗原。 作为优选实施方案，本发明的抗体衍生自mAB 425（ATCC HB 9629）或其人源化或嵌合衍生物。
-
公开(公告)号：US5844093A
公开(公告)日：1998-12-01
申请号：US553497
申请日：1995-11-17
申请人： A. Cathrine Kettleborough , Mary M. Bendig , Keith H. Ansell , Detlef Gussow , Jaume Adan , Francesc Mitjans , Elisabet Rosell , Francesc Blasco , Jaume Piulats
发明人： A. Cathrine Kettleborough , Mary M. Bendig , Keith H. Ansell , Detlef Gussow , Jaume Adan , Francesc Mitjans , Elisabet Rosell , Francesc Blasco , Jaume Piulats
IPC分类号： G01N33/53 , A61K38/00 , A61K39/395 , A61P35/00 , C07K16/00 , C07K16/28 , C12N15/09 , C12N15/13 , C12P21/02 , C12P21/08 , C12R1/19 , G01N33/563 , C07H21/04 , C12N15/63
CPC分类号： C07K16/00 , C07K16/2863 , A61K38/00 , C07K2319/00
摘要： This invention relates to new anti-EGFR antibodies and single-chain Fvs (scFvs) thereof which can be obtained from phage-antibody libraries constructed from cells of an immunized mammalian, preferably a mouse. Two of the single-chain Fvs isolated from the phage-antibody libraries were engineered to create partially humanized whole antibody molecules. These chimeric anti-EGFR antibodies contain constant regions of human immunoglobulins, and can be used as well as the single-chain Fvs as agents for the diagnosis and therapy of human tumors.
摘要翻译： PCT No.PCT / EP95 / 00978 371日期：1995年11月17日 102（e）日期1995年11月17日PCT 1995年3月16日PCT公布。 公开号WO95 / 25167 日期1995年9月21日本发明涉及可从免疫的哺乳动物，优选小鼠的细胞构建的噬菌体抗体文库获得的新的抗EGFR抗体及其单链Fvs（scFv）。 将从噬菌体 - 抗体文库分离的两条单链Fvs进行工程改造以产生部分人源化的全抗体分子。 这些嵌合抗EGFR抗体含有人免疫球蛋白的恒定区域，并且可以用作单链Fvs作为人肿瘤诊断和治疗的试剂。
-
公开(公告)号：US5985278A
公开(公告)日：1999-11-16
申请号：US574699
申请日：1995-12-19
申请人： Francesc Mitjans , Jaume Piulats , Elisabet Rosell , Jaume Adan , Simon Goodman , Diane Hahn
发明人： Francesc Mitjans , Jaume Piulats , Elisabet Rosell , Jaume Adan , Simon Goodman , Diane Hahn
IPC分类号： C12N15/02 , A61K38/00 , A61K39/00 , A61K39/395 , A61P35/00 , C07K16/00 , C07K16/18 , C07K16/28 , C12N5/00 , C12N5/10 , C12N5/12 , C12N5/20 , C12N15/06 , C12N15/13 , C12N15/16 , C12P21/08 , C12R1/91 , G01N33/00 , G01N33/574 , G01N33/577
CPC分类号： C07K16/2839 , A61K38/00
摘要： The invention relates to a novel monoclonal antibody, a hybridoma cell line producing said antibody, DNA sequences coding for said antibody, and amino acid sequences. The monoclonal antibody, a preferred embodiment of which is named 17E6, has the following properties:reacting only with the .alpha.V-chain of human .alpha.V-integrins,blocking the attachment to the integrin substrate of the .alpha.V-integrin bearing cell,triggering reversal of established cell matrix interaction caused by .alpha.V-integrins,blocking tumor development, andshowing no cytotoxic activity.
摘要翻译： 本发明涉及新型单克隆抗体，产生所述抗体的杂交瘤细胞系，编码所述抗体的DNA序列和氨基酸序列。 单克隆抗体，其优选实施方案名为17E6，具有以下性质：仅与人α-V-整联蛋白的αV链反应，阻断与负载αV-整联蛋白的细胞的整合素底物的连接，触发 逆转由α-V整合素引起的建立的细胞基质相互作用，阻断肿瘤发展，并且不显示细胞毒性活性。
-
4.发明申请4-Amino-5-Oxo-8-Phenyl-5H-Pyrido(2,3-D) Pyrimidine Derivatives as Tyrosine Kinase and Raf Kinase Inhibitors for the Treatment of Tumours 失效4-氨基-5-氧代-8-苯基-5H-吡啶并（2,3-D）嘧啶衍生物作为酪氨酸激酶和Raf激酶抑制剂治疗肿瘤公开(公告)号：US20080146560A1
公开(公告)日：2008-06-19
申请号：US11667173
申请日：2005-10-20
申请人： Guenter Hoelzemann , Karl-August Ackermann , Helene Grassier , Alfred Jonczyk , Wilfried Rautenberg , Gema Tarrason , Elisabet Rosell-Vives , Jaume Adan , Claudia Cases
发明人： Guenter Hoelzemann , Karl-August Ackermann , Helene Grassier , Alfred Jonczyk , Wilfried Rautenberg , Gema Tarrason , Elisabet Rosell-Vives , Jaume Adan , Claudia Cases
IPC分类号： A61K31/5377 , C07D401/14 , A61K31/4985 , A61P27/16 , A61P19/00 , A61P35/04 , C07D413/14
CPC分类号： C07D471/04
摘要： Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours
摘要翻译： 式（I）的化合物，其中R 6，R 7，R 8，R 9， Het 1，X和X'具有权利要求1所示的含义，是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，并且可用于治疗肿瘤
-
公开(公告)号：US07547695B2
公开(公告)日：2009-06-16
申请号：US10579222
申请日：2004-10-14
申请人： Guenter Hoelzemann , Helene Crassier , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
发明人： Guenter Hoelzemann , Helene Crassier , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
IPC分类号： A61K31/5355 , A61K31/519 , C07D413/12 , C07D471/04 , A61P35/00
CPC分类号： C07D471/04
摘要： The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumors.
摘要翻译： 本发明涉及式（I）化合物，其中R 1，R 2，R 3，R 4，R 5，R 6，R 7，R 8，R 9，X和X'具有专利权利要求1中引用的名称。所述化合物是酪氨酸激酶抑制剂， 特别是TIE-2和Raf激酶，并且可以特别地用于治疗肿瘤。
-
公开(公告)号：US20070225347A1
公开(公告)日：2007-09-27
申请号：US10593295
申请日：2005-03-15
申请人： Guenter Hoelzemann , Helene Crassier , Alfred Jonczyk , Wolfgang Staehle , Arne Sutter , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Riera
发明人： Guenter Hoelzemann , Helene Crassier , Alfred Jonczyk , Wolfgang Staehle , Arne Sutter , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Riera
IPC分类号： C07D233/00 , C07D233/66
CPC分类号： C07D233/90
摘要： Compounds of the formula (I), in which R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
摘要翻译： 式（I）的化合物，其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9， R 10，R 11，X和X'具有权利要求1所示的含义，是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，可以是 尤其用于治疗肿瘤。
-
7.发明授权4-Amino-5-oxo-8-phenyl-5H-pyrido(2,3-D) pyrimidine derivatives as tyrosine kinase and raf kinase inhibitors for the treatment of tumours 失效4-氨基-5-氧代-8-苯基-5H-吡啶并（2,3-D）嘧啶衍生物作为酪氨酸激酶和用于治疗肿瘤的raf激酶抑制剂公开(公告)号：US07745434B2
公开(公告)日：2010-06-29
申请号：US11667173
申请日：2005-10-20
申请人： Guenter Hoelzemann , Karl-August Ackermann , Helene Crassier , Alfred Jonczyk , Wilfried Rautenberg , Gema Tarrason , Elisabet Rosell-Vives , Jaume Adan , Claudia Cases
发明人： Guenter Hoelzemann , Karl-August Ackermann , Helene Crassier , Alfred Jonczyk , Wilfried Rautenberg , Gema Tarrason , Elisabet Rosell-Vives , Jaume Adan , Claudia Cases
IPC分类号： A61K31/535 , A61K31/50 , A61K31/495 , A01N43/58 , A01N43/60 , C07D413/00 , C07D471/00 , C07D487/00
CPC分类号： C07D471/04
摘要： Compounds of the formula (I), in which R6, R7, R8, R9, Het1, X and X′ have the meanings indicated in claim 1, are inhibitors of tyrosine kinases, in particular TIE-2, and Raf kinases and can be employed, inter alia, for the treatment of tumours.
摘要翻译： 式（I）化合物，其中R 6，R 7，R 8，R 9，Het 1，X和X'具有权利要求1所示的含义，是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，可以是 尤其用于治疗肿瘤。
-
公开(公告)号：US20070099910A1
公开(公告)日：2007-05-03
申请号：US10579222
申请日：2004-10-14
申请人： Guenter Hoelzemann , Helene Crassier , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
发明人： Guenter Hoelzemann , Helene Crassier , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
IPC分类号： A61K31/541 , A61K31/5377 , A61K31/519 , C07D487/02
CPC分类号： C07D471/04
摘要： The invention relates to compounds of formula (I) wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, X and X′ have the designations cited in patent claim 1. Said compounds are inhibitors of tyrosine kinases, especially TIE-2, and Raf kinases, and can, inter alia, be used for the treatment of tumours.
摘要翻译： 本发明涉及式（I）的化合物，其中R 1，R 2，R 3，R 4， R 5，R 6，R 7，R 8，R 9，R 9， X和X'具有专利权利要求1中引用的名称。所述化合物是酪氨酸激酶，特别是TIE-2和Raf激酶的抑制剂，并且特别可用于治疗肿瘤。
-
公开(公告)号：US20060241301A1
公开(公告)日：2006-10-26
申请号：US10566351
申请日：2004-07-02
申请人： Gunter Hoelzemann , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Helerie Crassier , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
发明人： Gunter Hoelzemann , Karl-August Ackermann , Wolfgang Staehle , Alfred Jonczyk , Wilfried Rautenberg , Helerie Crassier , Francesc Mitjans , Elisabet Rosell-Vives , Jaume Adan , Marta Soler Riera
IPC分类号： C07D471/02 , C07D285/10 , C07D277/62 , C07D319/14 , C07D307/02 , C07D209/18
CPC分类号： C07D213/69 , C07D209/08 , C07D213/70 , C07D213/81 , C07D235/32 , C07D277/64 , C07D277/82 , C07D285/14 , C07D307/86 , C07D317/64 , C07D319/18 , C07D471/04
摘要： The invention relates to novel urea derivatives which inhibit tyrosinkinases, especially TIE-2, and Raf kinases and which are used in the treatment of tumors.
摘要翻译： 本发明涉及抑制酪氨酸酶，特别是TIE-2和Raf激酶的新型脲衍生物，其用于治疗肿瘤。
-
公开(公告)号：US08562986B2
公开(公告)日：2013-10-22
申请号：US12669408
申请日：2008-07-17
申请人： Simon Goodman , Diane Hahn , Francesc Mitjans , Jaume Adan , Kin-Ming Lo
发明人： Simon Goodman , Diane Hahn , Francesc Mitjans , Jaume Adan , Kin-Ming Lo
IPC分类号： A61K39/395
CPC分类号： C07K16/2842 , A61K39/3955 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/565 , C07K2317/567 , C07K2317/72 , C07K2317/76 , C07K2317/90 , C07K2317/92 , A61K2300/00
摘要： The invention relates to engineered antibodies which specifically bind to integrin receptors, especially the alpha V integrin receptor subunit. The antibodies comprise the antigen binding sites (CDRs) of a known mouse anti-integrin antibody, as well as hybrid light chain variable sequences, mutated heavy chain variable sequences (Frs) and modified heavy chain constant sequences. The novel antibodies have improved immunogenic and expression properties and elicit excellent anti-angiogenic as well as anti-tumor activities in humans in monotherapy but also and above all in combination with other angiogenesis and tumor inhibiting agents.
摘要翻译： 本发明涉及特异性结合整联蛋白受体，特别是αV整联蛋白受体亚基的工程化抗体。 抗体包含已知小鼠抗整联蛋白抗体的抗原结合位点（CDR），以及杂交轻链可变序列，突变重链可变序列（Frs）和修饰的重链恒定序列。 新型抗体具有改善的免疫原性和表达性质，并且在单一疗法中引起人类优异的抗血管生成以及抗肿瘤活性，但也首先与其它血管生成和肿瘤抑制剂组合。
-
-
-
-
-
-
-
-
-
搜索结果
12 条记录 (耗时 0.024 秒)
